Metformin has also been linked to a host of separate pathways in PAH, including blocking the estrogen pathway through inhibiting aromatase transcription, decreasing Rho-kinase activity, and increasing prostacyclin synthase activity [11,164,165,166,167]. Here, CYP19A1 is linked to pulmonary arterial hypertension.